Business Description
Cabaletta Bio Inc
NAICS : 325412
SIC : 2834
2929 Arch Street, Suite 600, Philadelphia, PA, USA, 19104
Description
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAAR, T cells that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CAAR T cell product candidate was designed based on the clinically validated and commercially approved Chimeric Antigen Receptor, or CAR, T cell technology that is marketed for the treatment of B cell cancers.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | 0.94 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | 0 | |||||
| Beneish M-Score | 0 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -60.7 | |||||
| 3-Year EPS without NRI Growth Rate | 18.8 | |||||
| 3-Year FCF Growth Rate | -62.2 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 76.09 | |||||
| 9-Day RSI | 66.41 | |||||
| 14-Day RSI | 61.09 | |||||
| 6-1 Month Momentum % | -56.11 | |||||
| 12-1 Month Momentum % | -82.5 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 16.07 | |||||
| Quick Ratio | 16.07 | |||||
| Cash Ratio | 15.75 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -25.9 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -45.37 | |||||
| ROA % | -42.93 | |||||
| ROIC % | -1468.15 | |||||
| ROC (Joel Greenblatt) % | -3565.78 | |||||
| ROCE % | -45.43 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.42 | |||||
| Price-to-Tangible-Book | 0.42 | |||||
| EV-to-EBIT | 1.31 | |||||
| EV-to-EBITDA | 1.33 | |||||
| EV-to-FCF | 1.64 | |||||
| Price-to-Net-Current-Asset-Value | 0.42 | |||||
| Price-to-Net-Cash | 0.43 | |||||
| Earnings Yield (Greenblatt) % | 76.34 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Gurus Latest Trades with NAS:CABA
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0 | ||
| EPS (TTM) ($) | -1.84 | ||
| Beta | 0 | ||
| Volatility % | 95.13 | ||
| 14-Day RSI | 61.09 | ||
| 14-Day ATR ($) | 0.139133 | ||
| 20-Day SMA ($) | 1.328 | ||
| 12-1 Month Momentum % | -82.5 | ||
| 52-Week Range ($) | 0.9 - 14.9499 | ||
| Shares Outstanding (Mil) | 28.98 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Cabaletta Bio Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||